Syndax Announces Positive Pivotal Topline Results from Relapsed ...

Press Release Details · Syndax Announces Positive Pivotal Topline Results from Relapsed or Refractory mNPM1 AML Cohort in AUGMENT-101 Trial of ...

Syndax Announces Positive Pivotal Topline Results from Relapsed or Refractory mNPM1 AML Cohort in AUGMENT-101 Trial of Revumenib · In This ...

Syndax Pharmaceuticals, Inc. Announces Positive Pivotal Topline ...

Syndax Pharmaceuticals announced positive topline results from the relapsed or refractory mutant NPM1 acute myeloid leukemia cohort in the ...

Form 8-K for Syndax Pharmaceuticals INC filed 11/12/2024

... announcing positive topline results from the relapsed or refractory mutant NPM1 (“mNPM1”) acute myeloid leukemia cohort in the pivotal Phase ...

Syndax Pharmaceuticals (SNDX) Announces Positive Pivotal ...

StreetInsider · Syndax Pharmaceuticals (SNDX) Announces Positive Pivotal Topline Results from Relapsed or Refractory mNPM1 AML Cohort in AUGMENT- ...

Syndax: Home

Featured Content · Syndax Announces Positive Pivotal Topline Results from Relapsed or Refractory mNPM1 AML Cohort in AUGMENT-101 Trial of ...

Press Releases | Syndax Pharmaceuticals, Inc.

Press Releases · 11.12.24. Syndax Announces Positive Pivotal Topline Results from Relapsed or Refractory mNPM1 AML Cohort in AUGMENT-101 Trial of Revumenib.

Investors | Syndax Pharmaceuticals, Inc.

Syndax Announces Positive Pivotal Topline Results from Relapsed or Refractory mNPM1 AML Cohort in AUGMENT-101 Trial of Revumenib. – Primary endpoint met with ...

Press Releases | Syndax Pharmaceuticals, Inc.

Syndax to Announce Topline Results from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia and Host an Investor Call on ...

Syndax Announces Positive Pivotal Topline Results from Relapsed ...

Syndax Announces Positive Pivotal Topline Results from Relapsed or Refractory mNPM1 AML Cohort in AUGMENT-101 Trial of Revumenib ; January 31st, ...

Syndax Presents Positive Pediatric Data from Pivotal AUGMENT ...

"We are pleased to present positive results from pediatric patients treated with revumenib in the AUGMENT-101 pivotal trial demonstrating ...

AUGMENT-101 Trial of Revumenib Meets Primary End Point in ...

The AUGMENT-101 trial demonstrated that revumenib achieved a 23% complete remission rate in patients with relapsed/refractory KMT2A-rearranged acute leukemia.

Syndax's Revumenib Shows 88% Response Rate in Leukemia Trial ...

Syndax Pharmaceuticals reports breakthrough results for revumenib in leukemia treatment, achieving up to 88% response rates.

Syndax Announces Publication in the Journal of Clinical Oncology ...

... Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia ... Positive topline results from the Phase 2 AUGMENT-101 ...

Syndax Announces Data from Pivotal AUGMENT-101 Trial of ...

... Relapsed/Refractory KMT2Ar Acute Leukemia: Topline Efficacy and Safety Results from the Pivotal AUGMENT-101 Phase 2 Study Presenter: Ibrahim Aldoss, M.D.

Syndax to Announce Topline Results from Pivotal AUGMENT-101 ...

Syndax to Announce Topline Results from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia and Host an Investor ...

Press Releases | Syndax Pharmaceuticals, Inc.

... Pivotal AUGMENT-101 Trial of Revumenib in Relapsed ... 23. Syndax to Announce Topline Results from Pivotal ... Syndax and Incyte Announce Positive Topline Results ...

Syndax Announces Completion of Enrollment in AUGMENT-101 ...

Syndax Pharmaceuticals completes enrollment in pivotal trial for revumenib in mutant nucleophosmin acute myeloid leukemia, with topline data ...

Syndax to Announce Topline Results from Pivotal AUGMENT-101 ...

Highlights of the Company s pipeline include revumenib, a highly selective inhibitor of the menin-KMT2A binding interaction, and axatilimab, a ...

Syndax Announces Completion of Enrollment in AUGMENT-101 ...

... Pivotal Trial Cohort of Patients with Relapsed ... "We look forward to reporting topline data for this pivotal ... Positive topline results from the Phase 2 AUGMENT ...